newsfilter
← Latest News
PR Newswire·

Boston Scientific announces pricing of $3.0 billion and €4.25 billion offerings of senior notes

  • Boston Scientific Corporation priced a $3 billion USD offering consisting of four tranches of Senior Notes due 2029, 2031, 2033, & 2036 with interest rates ranging from 5.375% to 5.875%.
  • American Medical Systems Europe B.V., a wholly owned subsidiary, priced a €4.25 billion Euro offering comprising Floating Rate Notes due 2028 & five tranches of Senior Notes due 2028, 2030, 2034, 2038, & 2046 with interest rates from 3.875% to 5.125%.
  • The Euro Notes are fully & unconditionally guaranteed by Boston Scientific Corporation.
  • Both offerings are expected to close on December 1, 2026, & are not conditioned upon each other's completion.
  • Net proceeds will primarily finance the cash consideration for the acquisition of Penumbra, Inc., along with related fees, expenses, & general corporate purposes.
  • If the Penumbra Acquisition is not completed by the applicable date, most note series (excluding Floating Rate Notes) will trigger a special mandatory redemption at 101% of principal plus accrued interest.
  • The Offerings were made pursuant to a registration statement filed with the U.S. Securities & Exchange Commission.
  • Joint book-running managers for the USD Offering include BofA Securities, Citigroup, & J.P. Morgan, while Euro Offering managers include Barclays, Citigroup Europe, & J.P. Morgan SE.
Company
Boston Scientific Corporation
Keywords
Boston Scientific Corporation